



الرقم: ١١٨٧/أ.م. / 6/5

التاريخ: 2018/10/31

الإدارة
١١/٢٠١٨

المحترمين

السادة / هيئة الأوراق المالية


الموضوع: البيانات المالية الربع سنوية

تحية طيبة وبعد

نرفق لكم طيه البيانات المالية الموحدة الربع سنوية باللغة الانجليزية والمنتوية في 30 أيلول لعام 2018م ، لشركة البلاد للخدمات الطبية م . ع . م .


وتفضلوا بقبول فائق الاحترام والتقدير ،،،

المدير العام
احمد محمد الأحمد



نسخة :-

- بورصة عمان
- قسم شؤون المساهمين
- الصادر العام



AL BILAD FOR MEDICAL SERVICES COMPANY
(PUBLIC SHAREHOLDING COMPANY)
AMMAN - JORDAN

INTERIM CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (UNAUDITED)
TOGETHER WITH REVIEW REPORT
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2018

AL BILAD FOR MEDICAL SERVICES COMPANY
(PUBLIC SHAREHOLDING COMPANY)
AMMAN - JORDAN

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
TOGETHER WITH REVIEW REPORT
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2018

<u>Contents</u>	<u>Page</u>
Review report	-
Interim condensed consolidated statement of financial position	1
Interim condensed consolidated statement of profit or loss and other comprehensive income	2
Interim condensed consolidated statement of changes in equity	3
Interim condensed consolidated statement of cash flows	4
Notes forming part of the interim condensed consolidated financial statements	5-9

Review Report

To the shareholders of
Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Introduction

We have reviewed the interim condensed consolidated statement of financial position of **Al Bilad For Medical Services Company (Public Shareholding Company)** as at 30 September 2018 and the interim condensed consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows for the nine months then ended, and a summary of significant accounting policies and other explanatory information. Management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with IAS 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements (2410) "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us believe that the interim condensed consolidated financial statements do not present fairly from all material respects the interim condensed consolidated financial position for **Al Bilad For Medical Services Company (Public Shareholding Company)** as at 30 September 2018 and its interim condensed consolidated financial performance and its interim condensed consolidated cash flows for the nine months then ended, in accordance with IAS 34 "Interim Financial Reporting".

Samman & Co



Ahmad Ramahi
License (868)



29 October 2018
Amman - Jordan

Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Interim condensed consolidated statement of financial position
As at 30 September 2018

	Note	30 September 2018 (Unaudited) JOD	31 December 2017 (Audited) JOD
Assets			
Non current assets			
Property and equipment	(4)	19,068,864	18,621,894
Investment property		3,090,609	3,090,609
Investments in associate company		1,868,017	1,876,410
Investments in financial assets at fair value through other comprehensive income		82,854	243,706
Intangible assets		79,873	76,785
		<u>24,190,217</u>	<u>23,909,404</u>
Current assets			
Medicines and medical Supplies		786,086	791,950
Trade and other receivables	(5)	10,341,229	9,328,707
Cash and cash equivalents		2,702,314	3,352,573
		<u>13,829,629</u>	<u>13,473,230</u>
Total Assets		<u>38,019,846</u>	<u>37,382,634</u>
Equity and Liabilities			
Equity			
Authorized capital	(6)	30,000,000	30,000,000
Paid up capital		30,000,000	30,000,000
Statutory reserve		2,234,037	2,234,037
Accumulated change in fair value of investments in financial assets at fair value through other comprehensive income		(578,255)	(381,600)
Accumulated losses		(6,065,621)	(6,233,635)
Total Equity		<u>25,590,161</u>	<u>25,618,802</u>
Liabilities			
Non current liabilities			
Loans and bank facilities		-	80,367
Current liabilities			
Trade and other payables	(7)	9,288,323	8,528,585
Loans and bank facilities		3,106,211	3,154,880
Income tax provision	(8)	35,151	-
		<u>12,429,685</u>	<u>11,683,465</u>
Total liabilities		<u>12,429,685</u>	<u>11,763,832</u>
Total equity and liabilities		<u>38,019,846</u>	<u>37,382,634</u>

The Interim condensed consolidated financial statements on pages [1] to [9] were approved and authorized for issue by the Board of Directors on 28 October 2018 and were signed by:

General Manager

Chairman

Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Interim condensed consolidated statement of profit or loss and other comprehensive income (Unaudited)
for the nine months ended 30 September 2018

	Note	For the three months ended 30		For the nine months ended 30	
		September		September	
		2018	2017	2018	2017
		JOD	JOD	JOD	JOD
Revenue		3,381,294	2,854,674	9,302,589	8,751,504
Cost of revenue		(2,099,315)	(1,846,437)	(5,949,940)	(5,670,940)
Gross profit		1,281,979	1,008,237	3,352,649	3,080,564
Other revenue		135,554	194,623	519,850	413,367
Administrative expenses		(1,240,758)	(1,173,519)	(3,652,801)	(3,380,279)
Operating profit		176,775	29,341	219,698	113,652
Bank interests revenue		32,054	34,554	102,440	121,257
Share of profits of equity accounted associate		(5,780)	4,343	27,409	17,601
Financing costs		(52,535)	(39,889)	(146,382)	(121,198)
Profit for the period before tax		150,514	28,349	203,165	131,312
Income tax	(8)	(31,259)	(12,192)	(35,151)	(22,973)
Profit for the period		119,255	16,157	168,014	108,339
Other comprehensive income					
Change in fair value of investments in financial assets at fair value through other comprehensive income		(34,659)	(71,273)	(196,655)	(148,899)
Total comprehensive loss		84,596	(55,116)	(28,641)	(40,560)
Profit Per Share - Piaster/ share				0.01	0.004

Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Interim condensed consolidated statement of changes in equity (Unaudited)
for the nine months ended 30 September 2018

	Paid up capital	Statutory reserve	Accumulated change in fair value of investments in financial assets at fair value through other comprehensive income	(Accumulated losses) Retained earnings	Total
	JOD	JOD	JOD	JOD	JOD
<u>30 September 2018</u>					
1 January 2018	30,000,000	2,234,037	(381,600)	(6,233,635)	25,618,802
Total comprehensive loss	-	-	(196,655)	168,014	(28,641)
<u>30 September 2018</u>	<u>30,000,000</u>	<u>2,234,037</u>	<u>(578,255)</u>	<u>(6,065,621)</u>	<u>25,590,161</u>
<u>30 September 2017</u>					
1 January 2017	30,000,000	2,234,037	(257,186)	2,639,367	34,616,218
Total comprehensive loss	-	-	(148,899)	108,339	(40,560)
<u>30 September 2017</u>	<u>30,000,000</u>	<u>2,234,037</u>	<u>(406,085)</u>	<u>2,747,706</u>	<u>34,575,658</u>

Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Interim condensed consolidated statement of cash flows (Unaudited)
for the nine months ended 30 September 2018

	Note	2018 JOD	2017 JOD
<u>Operating activities</u>			
Profit for the period before tax		203,165	131,312
<i>Adjustments for:</i>			
Depreciation and amortization	(4)	1,020,962	1,074,261
Share of profits of equity accounted associate		(27,409)	(17,601)
Financing costs		146,382	121,198
Bank interests		(102,440)	(121,257)
Gain from sale of property and equipment		(23,350)	-
		<u>1,217,310</u>	<u>1,187,913</u>
Medicines and medical Supplies		5,864	262,694
Trade and other receivables	(5)	(982,523)	(773,883)
Trade and other payables	(7)	759,738	(1,155,496)
Cash generated from operation		<u>1,000,389</u>	<u>(478,772)</u>
Income tax paid		-	(386,814)
Cash flows generated from (used in) operating activities		<u>1,000,389</u>	<u>(865,586)</u>
<u>Investing activities</u>			
Purchase of property and equipment		(622,427)	(320,085)
Cash proceeds from sale of property and equipment		23,350	-
Purchase of intangible assets		(20,702)	(29,932)
Projects under construction		(827,891)	(1,250,640)
Cash flows used in investing activities		<u>(1,447,670)</u>	<u>(1,600,657)</u>
<u>Financing activities</u>			
Loans and bank facilities		(129,036)	1,217,068
Paid financing costs		(146,382)	(121,198)
Received interest		72,440	101,257
Cash flows (used in) generated from financing activities		<u>(202,978)</u>	<u>1,197,127</u>
Decrease in cash and cash equivalents during the period		(650,259)	(1,269,116)
Cash and cash equivalents - beginning of the period		<u>3,352,573</u>	<u>4,667,350</u>
Cash and cash equivalent - end of the period		<u>2,702,314</u>	<u>3,398,234</u>

**Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan**

**Notes forming part of the Interim condensed consolidated financial statements
For the nine months ended 30 September 2018**

1) General

Al Bilad For Medical Services Company was established on 26 November 1996 as a public shareholding company in the Register of Public Shareholding Companies under No. 323.

The main objective of the company is to establish a general hospital to provide health, preventive, diagnostic and therapeutic services.

The company's main address is: Amman - Arjan.

The following are the names of the board members:

<u>Name</u>	<u>Position</u>
HE Sheikh Fahad bin Mohammed bin Saleh Al-Athel	Chairman
HE Dr. Nayef Hayel Falih Al Fayez	Deputy Chairman
Arab General Medical Services Company Ltd. represented by Turki Bin Fahad Mohammed Al Athel	Board Member
Mohammed Tayseer Morshed Al Haj Hassan Abu Rajab	Board Member
Hashem Odeh Al Fadhel Al Fadhel	Board Member
Mustafa Ahmed Abdulhafeez Salhab	Board Member
Bassam Ahmad Mohammed Jrrar	Board Member
Mohammed Rashed Thiab Hasan	Board Member
Saleh Hassan Saleh Abu Rumah	Board Member

The interim condensed consolidated financial statements of the Group include the financial statements of the Parent Company (Al Bilad For Medical Services Company), its subsidiary and associate companies, the following is information about the subsidiary:

<u>Company</u>	<u>Country of incorporation</u>	<u>Activity</u>	<u>Percentage of ownership%</u>
Al Bilad Al Khadra Real Estate Investment Company	Jordan	Possession of land to implement	100

2) Summary of significant accounting policies

Basis of preparation

The interim condensed consolidated financial statements have been prepared in accordance with IAS (34) "Interim Financial Reporting" and in accordance with local standard. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the 2017 annual report.

The interim condensed consolidated financial statements are presented in Jordanian Dinar (JOD), which is also the Group's functional currency. Amounts are rounded to the nearest JOD.

Notes forming part of the Interim condensed consolidated financial statements
For the nine months ended 30 September 2018 (continued)

The preparation of interim condensed consolidated financial statements in compliance with IAS (34) "Interim Financial Reporting" requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the company's accounting policies.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those used in the preparation of the financial statements for the year ended 31 December 2017. Except for new standards, interpretations and amendments that are effective for the first time for periods beginning on or after 1 January 2018 that will be adopted in the annual financial statements for 2018.

New standards impacting the Group that will be adopted in the annual financial statements for the year ended 31 December 2018 are: IFRS 9 "Financial Instruments"; and IFRS 15 "Revenue from Contracts with Customers".

IFRS 9 "Financial Instruments":

During the current period, the Group has adopted the new and amended IFRSs and improvements to IFRSs effective 1 January 2018, which include IFRS 9 "Financial Instruments" which was replaced by IAS 39 "Financial Instruments: Recognition and Measurement", whereby impairment provision for financial assets measured at amortized cost (trade and other receivables) in accordance with the provision for loss incurred under IFRS 9, which differs from the loss model previously incurred under IAS 39.

IFRS 15 "Revenue from Contracts with Customers".

This standard has been replaced by IAS 18 "Revenue" and IAS 11 "Construction Contracts" where the Standard states the revenue recognition based on the following steps:

1. Determine the contract with the client.
2. Defining performance obligations in the contract.
3. Determine the contract price.
4. Distribution of contract price on performance obligations.
5. Recognition of revenue when performance obligations are met.

The adoption of the above IFRSs has no significant effect on the interim condensed consolidated financial statements for the period ended 30 September 2018.

Use of estimates and judgements

There have been no material adjustments to the nature and amount of estimates and judgments used in the annual financial statements for the year ended 2017 except of the issues where the implementation of IFRS 9 "Financial instruments" discussed above is required.

The significant estimates and judgments required to implement this new standard are to estimate the impairment of trade and other receivables in the short term for the purposes of the expected loss model in accordance with IFRS 9.

Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Notes forming part of the Interim condensed consolidated financial statements
For the nine months ended 30 September 2018 (continued)

Basis of consolidation of financial statements

When the Company has control over the investee, it is considered a subsidiary. Control is achieved when all six elements are available: the power in the investee company, the right to variable returns, and the ability to use power to influence the amount of variable returns. The control shall be re-evaluated if any facts or indications of a possible change in any of the above-mentioned elements have occurred.

The consolidated financial statements include the results of the Company and the subsidiary as if they form together a single entity and therefore the transactions and balances between the two companies are fully eliminated.

The consolidated financial statements include the results of the business combination using the acquisition method whereby the assets and liabilities of the subsidiary are recognized at fair value at the date of acquisition and their operating results are taken to the statement of profit or loss and other comprehensive income from the date of acquisition, and its recognitions stops in case of losing control.

3) Use of estimates and judgments

There have been no material revisions to the nature and amount of changes in estimates and Judgments used in the annual consolidated financial statements 2017.

4) Property and equipment

The additions of property, equipment and projects under construction during the nine months ended 30 September 2018 amounted to JOD 1,450,318 (31 December 2017: JOD 3,284,347).

The depreciation expense of property and equipment for the nine months ended 30 September 2018 amounted to JOD 1,003,348 (30 September 2017: JOD 1,058,061).

5) Trade and other receivables

	30 September 2018 (Unaudited) JOD	31 December 2017 (Audited) JOD
Trade receivables	23,795,229	23,797,025
Cheques under collection	7,125	16,162
Provision for impairment of trade receivables	(14,668,514)	(15,594,492)
Net trade receivables	9,133,840	8,218,695
Due from related parties	1,726	2,194
Accrued revenue	614,572	569,767
Employees receivables	68,956	44,672
Insurances	270,045	263,345
Total financial assets classified as loans and account receivable other than cash and cash equivalents	10,089,139	9,098,673
Prepaid expenses	245,761	225,262
Income tax deposits	6,329	4,772
	10,341,229	9,328,707

Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Notes forming part of the Interim condensed consolidated financial statements
For the nine months ended 30 September 2018 (continued)

6) Equity

Paid up capital

The authorized capital is JOD (30) million divided into (30) million shares where the value is 1 JOD per share.

Statutory reserve

The accumulated amounts in this reserve represents 10% of annual profits before tax and fees and it's not distributable to the shareholders. The group may stop deducting statutory reserve when it reaches 25% of the capital. However, the group may with the approval of the General Assembly, continue to deduct this annual ratio until this reserve equals the capital of the group in full.

Accumulated change in fair value of investments in financial assets at fair value through other comprehensive income

Represents the profits or losses arising from the valuation of financial assets classified as investments in financial assets at fair value through other comprehensive income.

Accumulated losses

This item contains only profit, loss and dividends.

7) Trade and other payables

	30 September 2018 (Unaudited) JOD	31 December 2017 (Audited) JOD
Trade payable	3,777,419	4,252,384
Accrued expenses	2,760,840	2,202,488
Deferred cheques	2,008,724	1,415,009
Total financial liabilities other than loans and bank facilities	8,546,983	7,869,881
Income tax deposits	86,467	88,228
Social security deposits	78,593	66,439
Unearned revenue	75,256	41,123
Patients deposits	68,857	51,469
Other	432,167	411,445
	9,288,323	8,528,585

Al Bilad For Medical Services Company
(Public Shareholding Company)
Amman - Jordan

Notes forming part of the Interim condensed consolidated financial statements
For the nine months ended 30 September 2018 (continued)

8) Income tax provision

The income tax provision amounted to JOD 35,151 representing 20% of net profit amounted JOD 175,756 for the nine months ended 30 September 2018, after deducting the Share of profits of equity accounted associate. This percentage represents the tax rate expected to be applied till the end of the year.

9) Contingent liabilities

Lawsuits

According to correspondence with the group's lawyers, the amount of lawsuits against the group is JOD 1,500,000.

Bank guarantees

At the interim condensed consolidated statement of financial position date, the Group had contingent liabilities against bank guarantees amounted to JOD 114,770 (31 December 2017: JOD 80,770).

10) Comparative figures

We have reclassified some of the comparative interim condensed consolidated financial statements figures for the nine months ended 30 September 2017 to match with classification used in the interim condensed consolidated financial statements figures for the nine months ended 30 September 2018, reclassification did not have any impact on the retained earnings for the period ended at that date.